Consistent with this hypothesis, clinical trials of monoclonal antibodies to IL-13 or its receptor in patients with asthma have consistently shown increases in peripheral blood eosinophil counts46–48, and tissue eosinophilia was decreased in a recent phase 2 study of anti–IL-13 antibody in EoE49. This evidence concerns the gene IL13 and asthma.